|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006560,
umls-concept:C0011900,
umls-concept:C0026764,
umls-concept:C0039736,
umls-concept:C0087111,
umls-concept:C0229671,
umls-concept:C0332293,
umls-concept:C0871261,
umls-concept:C1274040,
umls-concept:C1521761,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-10-15
|
|
pubmed:abstractText |
Few studies have focused on factors affecting outcome in patients with multiple myeloma (MM) treated with thalidomide-based therapy. We investigated factors affecting response, progression-free survival (PFS), and overall survival (OS) in patients with MM treated with the thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) regimen with the aim to select patients benefiting more from this therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1557-9190
|
|
pubmed:author |
pubmed-author:AlesianiFrancescoF,
pubmed-author:BrunoriMarinoM,
pubmed-author:BurattiniMaurizioM,
pubmed-author:CandelaMarcoM,
pubmed-author:CatariniMassimoM,
pubmed-author:CenturioniRiccardoR,
pubmed-author:CorvattaLauraL,
pubmed-author:FerrantiMarioM,
pubmed-author:GalieniPieroP,
pubmed-author:GiuliodoriLucianoL,
pubmed-author:LeoniPietroP,
pubmed-author:MarconiMonicaM,
pubmed-author:MeleAnnaA,
pubmed-author:OffidaniMassimoM,
pubmed-author:PiersantelliMaria-NovellaMN,
pubmed-author:PolloniClaudiaC,
pubmed-author:VisaniGiuseppeG
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
294-9
|
|
pubmed:meshHeading |
pubmed-meshheading:18854284-Aged,
pubmed-meshheading:18854284-Anthracyclines,
pubmed-meshheading:18854284-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18854284-Biological Markers,
pubmed-meshheading:18854284-C-Reactive Protein,
pubmed-meshheading:18854284-Disease-Free Survival,
pubmed-meshheading:18854284-Female,
pubmed-meshheading:18854284-Humans,
pubmed-meshheading:18854284-Male,
pubmed-meshheading:18854284-Middle Aged,
pubmed-meshheading:18854284-Multiple Myeloma,
pubmed-meshheading:18854284-Neoplasm Staging,
pubmed-meshheading:18854284-Prognosis,
pubmed-meshheading:18854284-Risk Factors,
pubmed-meshheading:18854284-Survival Analysis,
pubmed-meshheading:18854284-Thalidomide,
pubmed-meshheading:18854284-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy.
|
|
pubmed:affiliation |
Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti Ancona, Italy. m.offidani@ospedaliriuniti.marche.it
|
|
pubmed:publicationType |
Journal Article
|
